Cue Biopharma, Inc.

NasdaqCM:CUE Lagerbericht

Marktkapitalisierung: US$66.2m

Cue Biopharma Management

Management Kriterienprüfungen 2/4

Cue Biopharma's CEO ist Dan Passeri, ernannt in Aug 2016, hat eine Amtszeit von 7.75 Jahren. Die jährliche Gesamtvergütung beträgt $3.02M, bestehend aus 20.1% Gehalt und 79.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.28% der Aktien des Unternehmens, im Wert von $218.69K. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6 Jahre bzw. 5.9 Jahre.

Wichtige Informationen

Dan Passeri

Geschäftsführender

US$3.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts20.1%
Amtszeit als Geschäftsführer7.8yrs
Eigentum des Geschäftsführers0.3%
Durchschnittliche Amtszeit des Managements6.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6yrs

Jüngste Management Updates

Recent updates

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10
Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18
Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12
Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19
Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04
We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer

Jun 10

Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth

Jun 07
Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth

Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients

May 10

How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?

Mar 21
How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?

We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate

Feb 22
We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate

Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?

Jan 27
Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?

Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022

Jan 07

Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year

Dec 25
Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year

Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)

Nov 29
Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)

We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate

Nov 24
We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dan Passeri im Vergleich zu den Einnahmen von Cue Biopharma verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$3mUS$605k

-US$51m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$1mUS$748k

-US$53m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$2mUS$531k

-US$44m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$6mUS$501k

-US$45m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$395k

-US$37m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$45m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$834kUS$345k

-US$39m

Sep 30 2018n/an/a

-US$38m

Jun 30 2018n/an/a

-US$30m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$410kUS$325k

-US$23m

Vergütung im Vergleich zum Markt: DanDie Gesamtvergütung ($USD3.02M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD659.68K).

Entschädigung vs. Einkommen: DanDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Dan Passeri (63 yo)

7.8yrs

Amtszeit

US$3,015,480

Vergütung

Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Daniel Passeri
CEO & Director7.8yrsUS$3.02m0.28%
$ 183.0k
Anish Suri
President & Chief Scientific Officer6.1yrsUS$1.21m0.28%
$ 184.5k
Kerri-Ann Millar
Chief Financial Officer6.1yrsUS$1.16m0.029%
$ 19.5k
Ronald Seidel
Co-Founderno dataUS$316.63kkeine Daten
Rodolfo Chaparro
Co-Founder & Senior Advisorno dataUS$316.63kkeine Daten
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Boardno datakeine Datenkeine Daten
Colin Sandercock
Senior VP6.5yrsUS$625.51kkeine Daten
Matteo Levisetti
Chief Medical Officer3.3yrskeine Daten0.019%
$ 12.5k

6.1yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von CUE ist erfahren und erfahren (durchschnittliche Amtszeit: 6 Jahre).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Daniel Passeri
CEO & Director7.8yrsUS$3.02m0.28%
$ 183.0k
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Board9.4yrskeine Datenkeine Daten
Frederick Driscoll
Independent Director6yrsUS$76.31k0%
$ 0
Frank Morich
Independent Chairman of the Board5.9yrsUS$106.27k0.058%
$ 38.1k
Peter Kiener
Independent Director8.3yrsUS$144.18k0.00073%
$ 482.9
David Baker
Member of Scientific & Clinical Advisory Boardno datakeine Datenkeine Daten
Hidde L. Ploegh
Member of Scientific & Clinical Advisory Boardno datakeine Datenkeine Daten
Rafi Ahmed
Member of Scientific Advisory Board1.3yrskeine Datenkeine Daten
Kenneth Pienta
Clinical Advisor1.4yrskeine Datenkeine Daten
Abul K. Abbas
Member of Scientific Advisory Board3.3yrskeine Datenkeine Daten
Karolina Palucka
Member of Scientific & Clinical Advisory Board7.3yrskeine Datenkeine Daten
Michael Kalos
Member of Scientific Advisory Board3.3yrskeine Datenkeine Daten

6.0yrs

Durchschnittliche Betriebszugehörigkeit

67.5yo

Durchschnittliches Alter

Erfahrener Vorstand: CUEDie Vorstandsmitglieder gelten als erfahren (5.9 Jahre durchschnittliche Amtszeit).